MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Waltham, Massachusetts Friday, November 15, 2024, 15:00 Hrs [IST] ...

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ...

Gyre Therapeutics Inc ( (GYRE) ) has released its Q3 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its ...

EXCLUSIVE: The Industrial Injuries Advisory Council is advising ministers to offer this support to Covid victims still ...

Researchers are trying to get to the root of the problem, in hopes of helping these patients who are suffering the longest.